🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 06 Jul 2026 · EMA CTIS official data

Clinical Trials in Finland

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

23
Recent authorisations
12
Phase III trials
Finland
Selected country
Phase III Neoplasms Authorised 01/07/2026
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S · 189 participants
📍 Finland · Belgium · France · Denmark · Austria · Germany · Italy · Czechia · Norway
2025-522167-15-00 on CTIS ↗
Phase III Neoplasms Authorised 26/06/2026
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Pancreatic Ductal Adenocarcinoma
Incyte Corp. · 205 participants
📍 Poland · Italy · Netherlands · Sweden · Denmark · Finland · Spain · France · Belgium · Norway · Austria
2025-525009-18-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 24/06/2026
Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel
Bioequivalence, musculoskeletal pain pain
Fysioline Oy · 34 participants
📍 Finland
2026-526434-21-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company · 318 participants
📍 Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase II Neoplasms Authorised 15/06/2026
A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy
Multiple myeloma (RRMM)
Odense University Hospital · 50 participants
📍 Finland · Denmark · Estonia · Norway
2025-522114-23-00 on CTIS ↗
Phase I Neoplasms Authorised 08/06/2026
A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation
adenocarcinoma of the colon or rectum
Bayer Consumer Care AG · 49 participants
📍 Finland · Spain · Sweden · Italy · Denmark · Netherlands · Belgium
2025-523648-11-00 on CTIS ↗
Phase II Neoplasms Authorised 05/06/2026
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer
Gastric cancer
Varsinais-Suomen hyvinvointialue · 80 participants
📍 Finland
2026-526494-42-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 05/06/2026
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
Multiple Sclerosis; Primary Progressive Multiple Sclerosis; non-active Secondary Progressive Multiple Sclerosis
Sundance Biosciences Inc. · 30 participants
📍 Finland
2026-525817-29-00 on CTIS ↗
Phase III Therapeutics Authorised 29/05/2026
Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)
Deformity, Osteoarthritis
HUS-yhtymae · 450 participants
📍 Finland
2026-526142-27-01 on CTIS ↗
Phase I/II Neoplasms Authorised 22/05/2026
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
Neoplasms benign malignant and unspecified (incl. cysts and polyps)
Orion Corporation · 85 participants
📍 Finland · Denmark · Spain · France
2025-524620-22-00 on CTIS ↗
Phase I Neoplasms Authorised 21/05/2026
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
Neoplasms
Glaxosmithkline Research & Development Limited · 52 participants
📍 Spain · Denmark · Finland · France
2025-524165-25-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 18/05/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC · 398 participants
📍 Italy · Finland · Bulgaria · Greece · Belgium · Estonia · Portugal · Spain · Germany · France · Czechia · Slovakia · Romania · Croatia · Poland · Austria · Netherlands · Denmark · Sweden · Hungary
2025-524316-11-00 on CTIS ↗
Phase III Neoplasms Authorised 15/05/2026
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 265 participants
📍 Portugal · Norway · Sweden · Bulgaria · France · Belgium · Austria · Germany · Finland · Poland · Romania · Netherlands · Spain · Italy · Hungary · Czechia
2025-523586-18-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/05/2026
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Advanced Solid Tumors
Eikon Therapeutics Inc. · 49 participants
📍 France · Spain · Norway · Italy · Germany · Austria · Poland · Finland
2026-525248-13-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
advanced or metastatic extrapulmonary neuroendocrine carcinoma
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 144 participants
📍 Portugal · Spain · Poland · Sweden · Italy · Czechia · France · Netherlands · Finland · Denmark · Austria · Germany · Belgium · Norway
2025-523869-22-00 on CTIS ↗
Phase III Neoplasms Authorised 12/05/2026
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 295 participants
📍 Czechia · Sweden · Poland · Netherlands · Greece · Latvia · Finland · Norway · Belgium · Austria · Portugal · Romania · Italy · Estonia · France · Ireland · Germany · Spain · Bulgaria · Hungary
2025-520565-51-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 11/05/2026
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
Chronic rhinosinusitis with nasal polyps
Sanofi-Aventis Recherche & Developpement · 146 participants
📍 Germany · Netherlands · Portugal · Denmark · Sweden · Finland · France · Spain · Austria · Italy · Hungary · Romania · Belgium · Czechia · Poland
2025-522983-33-00 on CTIS ↗
Phase II Neoplasms Authorised 08/05/2026
FINACCESS - Finnish National Study for Early Access to Cancer Therapies
Cancer
HUS-yhtymae · 1500 participants
📍 Finland
2025-524769-26-00 on CTIS ↗
Phase III Immune System Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Janssen Cilag International · 271 participants
📍 Denmark · Hungary · Portugal · Italy · Norway · Greece · Slovakia · Czechia · France · Poland · Bulgaria · Germany · Spain · Romania · Finland
2025-523552-31-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations
Merck Sharp & Dohme LLC · 37 participants
📍 Czechia · Spain · Poland · Belgium · Finland · Germany · France · Netherlands · Hungary · Denmark
2025-524160-38-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
Ovarian cancer
Merck Sharp & Dohme LLC · 349 participants
📍 Norway · Ireland · Spain · Greece · France · Poland · Denmark · Austria · Hungary · Belgium · Czechia · Finland · Germany · Italy · Sweden
2023-508047-40-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 20/04/2026
CoCo-PCOS - Comprehensive Health Effects of Combined Contraceptives: a 6-month randomized, controlled, open-label trial of E4+DRSP, EE20µg+DRSP, and DRSP-only in women with PCOS
Contraception
Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu · 156 participants
📍 Finland
2025-523358-15-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 17/04/2026
CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial of E4+DRSP, EE20μg+DRSP and DRSP-only
Contraception
Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu · 156 participants
📍 Finland
2025-523359-71-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/finland (Accessed: 6 July 2026).

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker.